Complete Guide to Imatinib Pharmacokinetics
Overview
Imatinib is a Small Molecule used in the Oncology therapeutic area. It is indicated for CML / GIST. Population PK simulator for imatinib (Gleevec). Explore exposure-response and dose optimization in CML.
Mechanism of Action
Imatinib exerts its pharmacological effect by targeting BCR-ABL. As a Small Molecule, it modulates this target to achieve therapeutic efficacy in CML / GIST. Understanding the target engagement is critical for interpreting the pharmacokinetic-pharmacodynamic (PK/PD) relationship and optimizing dosing regimens.
Key Pharmacokinetic Parameters
The following parameters are derived from published PopPK models for Imatinib:
| Parameter | Value |
|---|---|
| ka | 0.5-1.0 h⁻¹ |
| CL F | 12-15 L/h |
| Tmax | 2-4 h |
| Vc F | 220 L |
| dose | 400-800 mg QD |
| IIV CL | 40% CV |
| t half | 18 h (parent), 40 h (metabolite) |
| Cmin target | >1000 ng/mL (CML) |
| bioavailability | 0.98 |
| protein binding | 95% (albumin + AGP) |
Parameters represent typical population estimates from published literature. Individual values may vary.
Dosing & Administration
Imatinib is administered via the Oral route. Oral administration involves absorption from the gastrointestinal tract, and bioavailability may be affected by food intake, formulation, and first-pass metabolism.
Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, Cmax, and Ctrough.
Clinical Considerations
In the Oncology therapeutic area, for the treatment of CML / GIST, understanding the pharmacokinetics of Imatinib is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect Imatinib pharmacokinetics include:
- •Body weight and body composition
- •Renal and hepatic function
- •Drug-drug interactions and concomitant medications
- •Age, sex, and genetic polymorphisms
Interactive Imatinib PK Simulator
Explore Imatinib pharmacokinetics interactively. Adjust doses, dosing intervals, and patient covariates to visualize concentration-time profiles in real time.
Frequently Asked Questions
What is the half-life of Imatinib?
The elimination half-life of Imatinib depends on patient-specific factors. Based on published models, the typical half-life is approximately 18 h (parent), 40 h (metabolite).
How is Imatinib administered?
Imatinib is administered via the Oral route. It is indicated for CML / GIST. As a Small Molecule, dosing regimens should follow approved prescribing information and clinical guidelines.
What are the key PK parameters of Imatinib?
Key pharmacokinetic parameters for Imatinib include clearance (CL), volume of distribution (Vd), and elimination half-life. See the PK Parameters section above for specific values from published models.
Can I simulate Imatinib dosing scenarios for free?
Yes! PKPDBuilder offers a completely free, interactive Imatinib PK simulator based on published pharmacometric models. No login required. Use it to explore different doses, dosing intervals, and patient covariates.
⚠️ Disclaimer
This guide is for research and educational purposes only. It is not intended for clinical decision-making or patient dosing. Parameters are derived from published literature and represent population estimates. Always consult approved prescribing information for clinical use.